BioNTech SE (NASDAQ:BNTX) Sees Large Growth in Short Interest

BioNTech SE (NASDAQ:BNTX - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,550,000 shares, a growth of 9.4% from the December 15th total of 2,330,000 shares. Based on an average daily volume of 806,600 shares, the short-interest ratio is currently 3.2 days.

Analysts Set New Price Targets

BNTX has been the subject of several research analyst reports. Evercore ISI upgraded BioNTech from an "in-line" rating to an "outperform" rating and raised their price target for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. Berenberg Bank began coverage on shares of BioNTech in a report on Tuesday, November 19th. They issued a "buy" rating and a $130.00 target price for the company. HSBC upped their price target on shares of BioNTech from $97.00 to $136.00 and gave the company a "buy" rating in a research note on Monday, October 7th. The Goldman Sachs Group raised shares of BioNTech from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $90.00 to $137.00 in a research note on Friday, November 8th. Finally, Morgan Stanley upgraded shares of BioNTech from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $142.72.

BioNTech Trading Down 0.7 %

BioNTech stock traded down $0.83 during mid-day trading on Friday, hitting $111.93. The company's stock had a trading volume of 458,339 shares, compared to its average volume of 565,513. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a 50 day moving average of $114.69 and a 200-day moving average of $104.76. BioNTech has a one year low of $76.53 and a one year high of $131.49. The stock has a market cap of $26.83 billion, a PE ratio of -53.30 and a beta of 0.18.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech's revenue was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.73 earnings per share. On average, research analysts anticipate that BioNTech will post -3.71 EPS for the current year.

Hedge Funds Weigh In On BioNTech

Several institutional investors have recently made changes to their positions in BNTX. GAMMA Investing LLC lifted its stake in shares of BioNTech by 21.7% during the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company's stock worth $74,000 after purchasing an additional 111 shares during the last quarter. Atomi Financial Group Inc. lifted its position in shares of BioNTech by 6.7% during the fourth quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company's stock valued at $414,000 after buying an additional 229 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after buying an additional 388 shares in the last quarter. Planning Capital Management Corp grew its position in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock worth $54,000 after buying an additional 450 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of BioNTech by 17.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,931 shares of the company's stock worth $465,000 after acquiring an additional 582 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.